Aspen Neuroscience and Bambusa Therapeutics Each Target $150 Million IPOs
Eric Friedman
The two clinical-stage biotechs are pursuing different markets—Parkinson’s disease and inflammatory conditions—but both are looking to fund the next stages of drug development.
Aspen Neuroscience and Bambusa Therapeutics have set terms for their initial public offerings, with each company seeking to raise $150.0 million at the midpoint of its proposed range. Both plan to offer 9.375 million shares at $15.00 to $17.00 per share and have applied to list on Nasdaq. San Diego-based Aspen Neuroscience, which is developing a personalized cell therapy for Parkinson’s disease, plans to trade under ASPE. Boston-based Bambusa Therapeutics, which is developing antibody treatments for inflammatory and immunological diseases, plans to trade under BBTX.
Aspen Neuroscience: A Personalized Approach to Parkinson’s Disease
Aspen Neuroscience is developing therapies for neurodegenerative diseases using cells derived from a patient’s own tissue. Its lead candidate, sasineprocel, is an investigational cell therapy being studied for Parkinson’s disease. The approach begins with a skin biopsy: the patient’s cells are reprogrammed into stem cells and then developed into dopamine-producing neurons intended for implantation in the brain.
The goal is to replace dopamine-producing neurons that have been lost as Parkinson’s progresses. The treatment is being evaluated as a one-time procedure, though its safety, effectiveness and durability remain under investigation.
Aspen is evaluating sasineprocel in its Phase 1/2a ASPIRO trial. As of the August 18, 2026 data cutoff, 15 patients had received the treatment, and the company reported that it was generally well tolerated, with most reported adverse events described as mild to moderate. The study is open-label, meaning patients and researchers know which treatment is being administered. Results from a small, early-stage study may not predict outcomes in a larger trial.
Following feedback from the FDA, Aspen expects to begin dosing patients in a Phase 3 trial in the second half of 2027. The company plans to use what it learns from ASPIRO—including information on dosing, surgical techniques and delivery procedures—to help inform the later-stage trial.
Aspen also intends to use its cell-therapy platform to pursue other neurodegenerative conditions. Its more advanced focus, however, remains sasineprocel, making progress in Parkinson’s disease especially important to the company’s near-term outlook.
At the $16.00 midpoint, Aspen’s offering would value the company at approximately $465.3 million, based on the 29.1 million shares expected to be outstanding after the offering. Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer & Co. are the underwriters.
Like many clinical-stage biotechs, Aspen has incurred substantial losses and expects to continue spending heavily on development. It reported a $62.1 million net loss in 2025 and a $36.5 million net loss in the first half of 2026. The company held approximately $72.4 million in cash, cash equivalents and marketable securities as of June 30, 2026. Proceeds from the IPO are intended to support sasineprocel’s clinical development, other research and development, and general corporate purposes.
For investors, Aspen’s opportunity rests on whether its patient-specific therapy can demonstrate meaningful and durable benefits in larger studies. The personalized manufacturing process and surgical delivery also present challenges that will need to be addressed as the program advances.
Bambusa Therapeutics: Targeting Inflammation From Two Directions
Bambusa Therapeutics is developing bispecific antibodies designed to target two disease
